Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 0.84 |
| ▸ | JAK1 | P23458 | 3/20 | 0.69 |
| ▸ | AXL | P30530 | 2/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.67 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.67 |
| ▸ | MERTK | Q12866 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379586 | 1.00 | JAK2 (0.84) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL14377767 | 1.00 | JAK2 (0.84) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL21412834 | 1.00 | JAK2 (0.84) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL16532750 | 0.95 | JAK2 (0.80) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL22449882 | 0.95 | JAK2 (0.80) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL22622522 | 0.94 | JAK2 (0.79) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL22449884 | 0.94 | JAK2 (0.79) | JAK2JAK1AXLPIK3CDTYRO3 | |
| SCHEMBL14331940 | 0.94 | JAK2 (0.83) | JAK2JAK1AXL | |
| SCHEMBL14376754 | 0.91 | JAK2 (1.00) | JAK2JAK1AXL | |
| SCHEMBL15801115 | 0.91 | JAK2 (1.00) | JAK2JAK1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4501409-A2 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | claimed |
| EP-3773593-B1 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | INCYTE CORP (US) | 2024-05-15 | — | — | EP | claimed |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2024-03-21 | — | — | US | claimed |
| US-20240058343-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | INCYTE CORPORATION | 2024-02-22 | — | — | US | claimed |
| CN-117120055-A | Combination therapy comprising a JAK pathway inhibitor and a ROCK inhibitor | 因赛特公司 | 2023-11-24 | — | — | CN | claimed |
| US-20220378791-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2022-12-01 | — | — | US | claimed |
| US-20220241286-A1 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | INCYTE CORPORATION | 2022-08-04 | — | — | US | claimed |
| US-20220226327-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION | 2022-07-21 | — | — | US | claimed |
| US-11324749-B2 | Combination therapy for treatment of hematological diseases | INCYTE CORPORATION (US) | 2022-05-10 | — | — | US | claimed |
| CN-113768927-A | Treatment of hidradenitis suppurativa with JAK inhibitors | 因赛特公司 | 2021-12-10 | — | — | CN | claimed |
| US-20160000795-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION (US) | 2016-01-07 | — | — | US | claimed |
| US-20150342952-A1 | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 | INCYTE CORPORATION (US) | 2015-12-03 | — | — | US | claimed |
| EP-2721028-B1 | AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS | INCYTE CORP (US) | 2015-11-04 | — | — | EP | claimed |
| WO-2015157257-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORPORATION (US) | 2015-10-15 | — | — | WO | claimed |
| US-20150246046-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2015-09-03 | — | — | US | claimed |
| US-20150225411-A1 | AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | claimed |
| US-9023840-B2 | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2015-05-05 | — | — | US | claimed |
| US-20150065447-A1 | SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS | INCYTE CORPORATION (US) | 2015-03-05 | — | — | US | claimed |
| US-20140171409-A1 | AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2014-06-19 | — | — | US | claimed |
| US-20130018034-A1 | AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2013-01-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000795-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | JAK2 1/4885JAK1 2/4885AXL 889/4885 |
| US-20130018034-A1 | AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885AXL 526/4885 |
| US-20220378791-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885AXL 1052/4885 |
| US-20150065447-A1 | SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS | JAK2, STAT3, IL6 | JAK2 1/4885JAK1 4/4885AXL 589/4885 |
| US-20150246046-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885AXL 1052/4885 |
| US-20150342952-A1 | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 | JAK1, JAK2, MCL1 | JAK2 2/4885JAK1 1/4885AXL 1833/4885 |
| US-20140171409-A1 | AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885AXL 526/4885 |
| US-20220241286-A1 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885AXL 2137/4885 |
| US-20150225411-A1 | AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885AXL 526/4885 |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | JAK2 1/4885JAK1 2/4885AXL 889/4885 |
| US-20220226327-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | JAK1, ROCK1, JAK3 | JAK2 8/4885JAK1 1/4885AXL 1369/4885 |
| US-11324749-B2 | Combination therapy for treatment of hematological diseases | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885AXL 1288/4885 |
| US-20240058343-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885AXL 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.